证券代码：600535 证券简称：天士力 公告编号：临2026-003 号 一、高级管理人员提前离任的基本情况 天士力医药集团股份有限公司（以下简称"公司"）董事会于 2026 年 3 月 6 日收到副总经理陆振先生提交的辞职报告，陆振先生由于个人原因，提请辞去公司 副总经理职务，辞任后陆振先生不再担任公司任何职务。 | | | | | | 是否继续在 | 是否存在 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | 原定任期到 | 离任原因 | 上市公司及 | 未履行完 | | | | | 期日 | | 其控股子公 | 毕的公开 | | | | | | | 司任职 | 承诺 | | 陆振 | 副总经理 | 2026.3.6 | 2027.5.7 | 个人原因 | 否 | 否 | 特此公告。 天士力医药集团股份有限公司 天士力医药集团股份有限公司董事会 关于公司高级管理人员辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、高级管理人 ...

Core Viewpoint - The pharmaceutical and biotechnology sector is expected to experience valuation recovery driven by policy and industry resonance in 2025, with the sector's PE (TTM) rising from 31x as of September 30, 2025, indicating a positive investment outlook [1][35]. Group 1: Market Review - The pharmaceutical sector's PE (TTM) has fluctuated between 21x and 53x since 2015, with an average of 33x, and has shown signs of recovery since Q1 2025 after hitting a low in September 2022 [1][11][45]. - The market capitalization of pharmaceutical stocks held by equity funds was 12.2% in Q2 2025, reflecting a 1.8 percentage point increase and indicating a recovery trend [12][49]. Group 2: Global Economic Context - The return to a rate-cutting environment globally, particularly with the Federal Reserve's rate cut in September 2025, is favorable for innovative assets, while global aging trends are driving increased healthcare spending [2][36][56]. - China's pharmaceutical innovation is gaining momentum, with expectations of capturing a larger share of the global pharmaceutical market, thus enhancing the competitiveness of the domestic industry [2][36]. Group 3: Investment Thesis - The investment strategy is framed around a three-stage clinical value model: 1. "0→1" technological breakthroughs in innovative drugs and devices, enhancing domestic capabilities [2][36]. 2. "1→10" clinical validation with high-quality domestic drugs accelerating overseas licensing [2][36]. 3. "10→100" efficiency in the Chinese pharmaceutical supply chain, with CXO companies achieving stable growth through cost advantages [2][36]. Group 4: Recommended Companies - Key companies recommended for investment include Innovent Biologics (H), Eifang Biologics (U), Tianshili, WuXi AppTec (A+H), Prasis, Mindray Medical, United Imaging Healthcare, and Weisi Medical [3][37].

Group 1 - In March 2025, China Resources Sanjiu acquired control of Tianshili for 5.99 billion yuan, resulting in an additional goodwill of 1.921 billion yuan [1][14] - The acquisition is part of a significant asset restructuring, with China Resources Sanjiu focusing on expanding its innovative traditional Chinese medicine business [14][15] - Tianshili's revenue for the first half of 2025 was 2.054 billion yuan, accounting for 13.87% of China Resources Sanjiu's consolidated revenue [15] Group 2 - Tianshili reported a total revenue of 8.236 billion yuan and a non-recurring net profit of 787 million yuan for 2025, reflecting a year-on-year decline of 3.08% and 24.06% respectively [16] - The decline in Tianshili's revenue is primarily attributed to a 14.24% decrease in pharmaceutical commercial income, mainly from chain pharmacy operations [16] - China Resources Sanjiu's revenue for 2025 was 31.629 billion yuan, with a year-on-year increase of 14.53% [16] Group 3 - The Tianjin Securities Regulatory Bureau issued four administrative penalties related to insider trading connected to the acquisition, indicating potential misuse of sensitive information [3][11] - The penalties involved individuals who traded stocks based on insider information during the sensitive period, with total illegal gains and fines imposed [12][13] - The stock of Tianshili saw a significant increase in trading volume and price following the announcement of the acquisition, with a single-day price increase of 6.18% on July 31, 2024 [13]

证券日报网讯2月13日，天士力（600535）在互动平台回答投资者提问时表示，公司目前经营正常，未 来公司将持续加强研发方面和销售方面的工作，努力提升企业价值。 ...

（文章来源：证券日报） 证券日报网讯 2月13日，天士力在互动平台回答投资者提问时表示，根据公司2025年度业绩快报，公司 归母净利润11亿元，同比增长15.68%。 ...

证券日报网讯 2月13日，天士力在互动平台回答投资者提问时表示，公司日常关联交易是公司生产经营 需要发生的日常经营性业务往来所需，以市场价格为基础协商定价，对公司持续经营能力、盈利能力等 不会产生不利影响。未来公司将持续加强研发和销售工作，努力提升公司价值。 （文章来源：证券日报） ...

证券日报网讯2月13日，天士力（600535）在互动平台回答投资者提问时表示，公司目前经营一切正 常，未来公司将持续加强研发工作以及销售工作，努力提升公司实际价值。 ...

Core Viewpoint - Recently, the company Tian Shi Li announced the termination of its cooperation agreement with the US company Arbor, halting the joint plan for the compound Danshen dripping pill (T89) in the US market. Although the company stated it would recover related rights and receive $7.5 million, and that this would not have a significant impact on its production and operations, the event reflects the multifaceted risks and challenges faced by Tian Shi Li in the internationalization of traditional Chinese medicine, research and development progress, and corporate operations [1][4]. Group 1: Internationalization Strategy Challenges - The compound Danshen dripping pill has been under FDA clinical application in the US since 1998, making it a landmark project for the internationalization of traditional Chinese medicine. However, the termination of the partnership with Arbor signifies a setback in the strategy of leveraging local partners for market entry [5][6]. - Despite the company emphasizing its accumulated international clinical experience and that the application process is not entirely dependent on Arbor, the exit of the partner undoubtedly increases the uncertainty of its independent advancement. Currently, the two indications for the drug—chronic stable angina and acute altitude sickness—are still in phase III clinical trials, with no clear timeline for final approval [6]. Group 2: Research and Development Progress and Regulatory Risks - The approval process for the compound Danshen dripping pill in the US has been fraught with difficulties. In 2017, the FDA required the company to complete a second confirmatory clinical trial in addition to an already completed phase III trial, with both trials needing to achieve statistical significance (p<0.05). The first trial took about four years, and the second trial, which started in 2018, has exceeded four years without results [2][6]. - This prolonged and high-investment clinical process not only brings financial pressure but also reflects the stringent challenges faced by traditional Chinese medicine formulations under Western regulatory systems. If the results of the second clinical trial do not meet the standards, years of effort may be wasted. The company's "lone battle" in the internationalization of traditional Chinese medicine—where only a few traditional Chinese medicine products have attempted to navigate the FDA—also makes it difficult to learn from peers, leading to high trial-and-error costs [2][6]. Group 3: Operational Difficulties and Transformation Challenges - The journey of the compound Danshen dripping pill abroad mirrors the development trajectory of Tian Shi Li in recent years. The company's revenue approached 19 billion yuan between 2016 and 2019, but has since been under pressure due to the sale of its marketing subsidiary and the impact of medical insurance cost control and centralized procurement policies. In 2025, the company's revenue was 8.236 billion yuan, a year-on-year decline of 3.08%, while the net profit excluding non-recurring items was 786 million yuan, down 24.06% year-on-year, indicating a continued lack of growth momentum [2][7]. - Additionally, the company officially integrated into the China Resources Sanjiu system in 2025, which may provide resource support but also means that its original development strategy will face adjustments. In the context of weak growth in its main business and slow internationalization progress, how Tian Shi Li repositions its core competitive path will be a key question for its future development [7]. Conclusion - The "American dream" of the compound Danshen dripping pill remains unfulfilled, while Tian Shi Li has entered a new development cycle. From self-research challenges to setbacks in cooperation, and from peak performance to integration and transformation, the case of this leading traditional Chinese medicine enterprise illustrates that the internationalization of traditional Chinese medicine involves not only technical compliance and clinical data but also a multifaceted test of corporate strategic determination, financial endurance, and market adaptability. The company still needs to find a feasible path to bridge traditional Chinese medicine and modern pharmaceutical systems [3][8].

Core Viewpoint - Tianshili has terminated its collaboration with Arbor Pharmaceuticals, impacting the U.S. market expansion plan for its compound Danshen dripping pill (T89), which was a key project for the internationalization of traditional Chinese medicine [1][4]. Group 1: Collaboration Termination - The termination of the partnership with Arbor was due to Arbor's acquisition by Azurity and subsequent business adjustments, leading to the end of the U.S. market cooperation plan for T89 [1][4]. - Tianshili will receive a payment of $7.5 million as part of the termination agreement and will regain exclusive sales rights for T89 in the U.S. [1][4]. - The company stated that this termination will not significantly impact its project advancement, production operations, or financial status [1][4]. Group 2: Historical Context of T89 - The internationalization of T89 began in 1998 when it was officially approved for clinical research by the U.S. FDA [3]. - T89 received FDA approval for indications related to chronic stable angina and acute altitude sickness in 2006 and 2018, respectively [4]. - Tianshili and Arbor signed a licensing agreement in September 2018, with Arbor committing up to $23 million for research and obtaining exclusive sales rights for T89 in the U.S. [4]. Group 3: Clinical Trials and Regulatory Challenges - Tianshili has accumulated significant overseas clinical trial experience prior to the collaboration with Arbor, having completed a large-scale Phase III clinical trial [4][5]. - The success of T89's U.S. market entry hinges on obtaining regulatory approval based on clinical data, with the product still awaiting approval [5][6]. - Tianshili is currently conducting two Phase III clinical trials for T89, with the results of the second trial being crucial for U.S. approval [6][9]. Group 4: Company Performance and Market Position - Tianshili is a leading company in the modern Chinese medicine sector, listed on the Shanghai Stock Exchange since 2002 [7]. - T89 is Tianshili's most recognized product, achieving sales of over 3.3 billion yuan in 2015 and maintaining its position as the top-selling traditional Chinese medicine product for 13 consecutive years [8]. - The company has faced declining revenues since 2020, with total revenue of 8.236 billion yuan in 2025, a decrease of 3.08% year-on-year, and a net profit decline of 24.06% [11].

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].